Ceftriaxon MIP (Ceftriaxone)

What Is Ceftriaxon MIP and What Is It Used For?

Quick answer: Ceftriaxon MIP contains ceftriaxone, a broad-spectrum third-generation cephalosporin antibiotic. It is administered by intravenous infusion to treat serious bacterial infections throughout the body, including pneumonia, meningitis, sepsis, and complicated urinary tract infections.

Ceftriaxone belongs to the cephalosporin class of beta-lactam antibiotics. Like all beta-lactams, it works by inhibiting bacterial cell wall synthesis. Specifically, ceftriaxone binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane, preventing the cross-linking of peptidoglycan chains that are essential for maintaining cell wall integrity. This leads to osmotic instability and ultimately bacterial cell death, making ceftriaxone a bactericidal rather than bacteriostatic agent.

As a third-generation cephalosporin, ceftriaxone has an extended spectrum of activity compared to first- and second-generation agents. It is particularly effective against Gram-negative organisms, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, and Neisseria meningitidis. It also retains useful activity against many Gram-positive organisms, including Streptococcus pneumoniae and Staphylococcus aureus (methicillin-sensitive strains only). Importantly, ceftriaxone has limited activity against anaerobes and is not effective against methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus species.

Ceftriaxon MIP is indicated for the treatment of the following infections when caused by susceptible organisms:

• Community-acquired pneumonia – one of the first-line parenteral options recommended by international guidelines
• Hospital-acquired pneumonia – particularly in combination with other agents
• Acute bacterial meningitis – ceftriaxone achieves therapeutic concentrations in cerebrospinal fluid
• Acute otitis media – when oral therapy is inappropriate or has failed
• Intra-abdominal infections – typically combined with metronidazole for anaerobic coverage
• Complicated urinary tract infections including pyelonephritis
• Bone and joint infections (osteomyelitis, septic arthritis)
• Complicated skin and soft tissue infections
• Gonorrhoea – recommended as first-line by WHO and many national guidelines
• Lyme disease (neuroborreliosis) – particularly for neurological and cardiac manifestations
• Sepsis and bacteraemia
• Surgical prophylaxis – particularly for colorectal, gynaecological, and orthopaedic procedures
• Endocarditis – in specific regimens as recommended by guidelines

One of the major pharmacokinetic advantages of ceftriaxone is its long elimination half-life of approximately 6 to 9 hours in adults, which is substantially longer than most other cephalosporins. This allows for convenient once-daily dosing in most clinical scenarios. Additionally, ceftriaxone has a unique dual elimination pathway: approximately 33-67% is excreted unchanged through the kidneys, and the remainder is eliminated via biliary excretion into the faeces. This means that moderate renal impairment does not typically require dose adjustment, although severe combined hepatic and renal impairment necessitates careful monitoring.

Ceftriaxone is included on the WHO Model List of Essential Medicines, reflecting its fundamental importance in global healthcare. It is classified as a "Watch" antibiotic under the WHO AWaRe (Access, Watch, Reserve) classification system, meaning it has a higher resistance potential and should be prioritised as key targets for stewardship and monitoring programmes.

What Should You Know Before Taking Ceftriaxon MIP?

Quick answer: Before receiving ceftriaxone, inform your healthcare provider about any allergies to cephalosporins, penicillins, or other beta-lactam antibiotics. Ceftriaxone has important contraindications, particularly in premature neonates and in patients requiring calcium-containing IV solutions.

Contraindications

Ceftriaxon MIP must not be used in the following circumstances:

• Hypersensitivity to ceftriaxone, any other cephalosporin, or to any of the excipients
• History of severe hypersensitivity (e.g., anaphylactic reaction) to any other type of beta-lactam antibiotic (penicillins, monobactams, carbapenems)
• Premature neonates up to a corrected age of 41 weeks (gestational age plus chronological age)
• Full-term neonates (up to 28 days) with jaundice, hyperbilirubinaemia, or hypoalbuminaemia – ceftriaxone may displace bilirubin from albumin binding, increasing the risk of bilirubin encephalopathy
• Full-term neonates who require (or are expected to require) treatment with intravenous calcium-containing solutions, including continuous calcium-containing infusions such as parenteral nutrition – due to the risk of formation of ceftriaxone-calcium precipitates

Warnings and Precautions

Healthcare providers should exercise caution and carefully weigh the benefits and risks in the following situations:

• Penicillin allergy: Patients with a history of allergy to penicillins may have cross-reactivity to cephalosporins. The estimated cross-reactivity rate is approximately 1-2% for third-generation cephalosporins, lower than historically believed, but severe reactions including anaphylaxis remain possible.
• Severe renal and hepatic impairment: In patients with both severe renal impairment (creatinine clearance <10 mL/min) and hepatic insufficiency, the daily dose should not exceed 2 g without close monitoring of serum ceftriaxone levels.
• Haemolytic anaemia: Immune-mediated haemolytic anaemia has been reported. If anaemia develops during treatment, the diagnosis should be considered, and ceftriaxone should be discontinued.
• Clostridioides difficile infection: As with nearly all antibiotics, ceftriaxone can disrupt normal intestinal flora and predispose patients to Clostridioides difficile-associated diarrhoea (CDAD), ranging from mild diarrhoea to fatal colitis. This should be considered in any patient developing diarrhoea during or after treatment.
• Biliary sludge and gallstones: Ceftriaxone can form calcium salt precipitates in the gallbladder, visible as shadows on ultrasound. This is generally asymptomatic and reversible upon discontinuation but may rarely cause symptomatic gallbladder disease, particularly with prolonged or high-dose therapy.
• Renal lithiasis: Cases of renal precipitates have been reported, primarily in children receiving high doses (≥80 mg/kg/day) or cumulative doses exceeding 10 g, and in those with additional risk factors such as dehydration or immobility.
• Pancreatitis: Rare cases of pancreatitis, possibly due to biliary obstruction, have been reported.
• Superinfection: Prolonged use may lead to overgrowth of non-susceptible organisms, including fungi.
• Interference with laboratory tests: Ceftriaxone may cause false-positive results in Coombs tests, galactosaemia testing, and some glucose monitoring methods (non-enzymatic/copper reduction methods).

Pregnancy and Breastfeeding

Ceftriaxone crosses the placental barrier. Preclinical animal studies have not demonstrated teratogenic effects, but there are limited well-controlled studies in pregnant women. Ceftriaxone should only be used during pregnancy if the expected benefit to the mother clearly outweighs the potential risk to the foetus. As with all medications, healthcare providers should apply the principle of using the minimum effective dose for the shortest duration necessary.

Ceftriaxone is excreted in low concentrations in human breast milk (approximately 3-4% of maternal serum concentrations). While the amounts transferred to the infant are small, breastfed infants could potentially experience diarrhoea, oral thrush (fungal infection of mucous membranes), or allergic sensitisation. A decision should be made whether to discontinue breastfeeding or to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

How Does Ceftriaxon MIP Interact with Other Drugs?

Quick answer: Ceftriaxone has several clinically important drug interactions. Most critically, it must never be combined with calcium-containing IV solutions. It may also enhance anticoagulant effects, increase nephrotoxicity risk with aminoglycosides, and produce false-positive results in certain diagnostic tests.

Drug interactions with ceftriaxone can be clinically significant and may affect efficacy, increase toxicity, or interfere with monitoring. Healthcare professionals should review the patient's complete medication list before administering ceftriaxone. The following table summarises the most important interactions:

Major Interactions

The most critical interaction is with calcium-containing intravenous solutions. Post-marketing reports have described cases where ceftriaxone-calcium precipitates formed in the lungs and kidneys of neonates who received ceftriaxone and calcium simultaneously. In some cases, the same intravenous infusion line was used, and precipitates were found in the line. At least one fatality has been reported. Although similar precipitates have not been reported in patients other than neonates, the risk is considered theoretical across all age groups when these are co-administered simultaneously.

The interaction with warfarin and other vitamin K antagonists is also clinically significant. Ceftriaxone may suppress the intestinal flora that produce vitamin K, potentially enhancing the anticoagulant effect. Patients on concurrent anticoagulant therapy should have their INR monitored frequently, and dose adjustments should be made accordingly. This is particularly important in patients who are critically ill, malnourished, or who have hepatic impairment.

When used together with aminoglycosides, there is both a pharmacological and pharmaceutical interaction. The combined nephrotoxic potential is additive, and the two drugs are physically incompatible — mixing them in the same solution results in precipitation and inactivation. They should be administered through separate infusion lines at different anatomical sites, or sequentially with adequate flushing between infusions.

Minor Interactions

Unlike many other beta-lactams, ceftriaxone's interaction with probenecid is minimal. Because a significant portion of ceftriaxone is eliminated via biliary excretion rather than purely renal tubular secretion, probenecid has little effect on its overall clearance. This is an important distinguishing feature from other cephalosporins where probenecid can significantly increase serum levels.

The effect on oral contraceptives is a theoretical concern based on the disruption of enterohepatic recirculation of oestrogen. While robust clinical evidence for this interaction is limited, current guidelines from many countries recommend advising patients to use additional barrier contraception during antibiotic therapy and for a short period afterwards.

What Is the Correct Dosage of Ceftriaxon MIP?

Quick answer: The standard adult dose is 1-2 g once daily by intravenous infusion. For severe or life-threatening infections, the dose may be increased to 4 g daily. Dosing in children is weight-based at 20-80 mg/kg/day. The infusion should be given over at least 30 minutes.

Ceftriaxon MIP must be reconstituted before administration. The 2 g powder is dissolved in the appropriate volume of compatible diluent (such as 0.9% sodium chloride or 5% glucose solution) and administered as an intravenous infusion over at least 30 minutes. The exact dilution volumes and procedures should follow the product's preparation instructions. Only freshly prepared solutions should be used.

Adults and Adolescents (≥12 years, ≥50 kg)

For most indications, the standard dose is 1-2 g once daily. The maximum recommended daily dose for adults is 4 g, used in severe or life-threatening infections such as bacterial meningitis. Treatment duration should be guided by the severity and nature of the infection, the clinical response, and relevant local or international treatment guidelines.

Children (15 days to 12 years, <50 kg)

In paediatric patients, the dose is calculated based on body weight and adjusted according to the type and severity of infection. For serious infections such as meningitis, higher doses are used to ensure adequate CSF penetration. Treatment should be continued for at least 48-72 hours after the patient becomes afebrile and cultures are negative, or as guided by clinical response.

Neonates (0-14 days)

Elderly Patients

No dose adjustment is required solely on the basis of age, provided renal and hepatic function are adequate. Elderly patients, however, are more likely to have reduced renal function, and concomitant conditions may necessitate careful dosing. If combined severe renal and hepatic impairment is present, the daily dose should not exceed 2 g and serum drug levels should be monitored. Elderly patients may also have an increased risk of Clostridioides difficile-associated diarrhoea and should be monitored closely.

Missed Dose

As Ceftriaxon MIP is administered by healthcare professionals in a clinical setting, the risk of missing a dose is minimised by hospital protocols. If a dose is inadvertently missed, it should be administered as soon as possible unless it is nearly time for the next scheduled dose. The dose should not be doubled to compensate. Maintaining consistent drug levels is important for the efficacy of antibiotic therapy and for minimising the risk of developing bacterial resistance.

Overdose

In the event of overdose, symptoms may include nausea, vomiting, and diarrhoea. Haemodialysis and peritoneal dialysis are not effective in removing ceftriaxone due to its high protein binding (approximately 85-95%). Treatment is supportive and symptomatic. In cases of very high overdose, particularly in patients with renal impairment, encephalopathic symptoms including confusion, altered consciousness, and myoclonus have been reported. Concentrations of ceftriaxone cannot be reduced by haemodialysis or peritoneal dialysis.

What Are the Side Effects of Ceftriaxon MIP?

Quick answer: Common side effects include diarrhoea, rash, and injection site reactions. Serious but less frequent effects include Clostridioides difficile-associated diarrhoea, biliary sludge, haemolytic anaemia, and allergic reactions including anaphylaxis. Most side effects are reversible upon discontinuation.

Like all antibiotics, ceftriaxone may cause side effects, although not everybody gets them. The frequency and severity of side effects vary between individuals. Many of the commonly reported effects are mild to moderate and resolve after treatment ends. However, some reactions can be serious and may require immediate medical attention. The following frequency grid summarises the known side effects based on post-marketing surveillance and clinical trial data:

The development of Clostridioides difficile-associated diarrhoea (CDAD) is one of the most clinically significant risks associated with ceftriaxone and other broad-spectrum antibiotics. CDAD can range from mild diarrhoea to life-threatening pseudomembranous colitis. Risk factors include advanced age, prolonged hospitalisation, concurrent use of other antibiotics, and use of proton pump inhibitors. If CDAD is suspected, ceftriaxone should be discontinued promptly, and appropriate therapy (e.g., oral vancomycin or fidaxomicin) should be initiated.

Biliary sludge is a relatively unique side effect associated with ceftriaxone. The mechanism involves the formation of insoluble calcium-ceftriaxone complexes in the gallbladder when biliary concentrations of ceftriaxone exceed its solubility limit. Ultrasound studies have shown that biliary precipitates can occur in up to 25-45% of patients receiving ceftriaxone, although the vast majority are asymptomatic. The condition is almost always reversible within days to weeks of discontinuing the drug. Risk factors include high doses, prolonged treatment, dehydration, and total parenteral nutrition.

Haematological effects are also noteworthy. While mild and transient leucopenia and thrombocytopenia are relatively common, severe immune-mediated haemolytic anaemia has been reported. This is a rare but potentially fatal complication that typically presents with a rapid decline in haemoglobin, jaundice, and a positive direct Coombs test. If haemolytic anaemia is suspected, ceftriaxone must be stopped immediately and the patient should receive appropriate supportive care including transfusion if necessary.

How Should You Store Ceftriaxon MIP?

Quick answer: Store the unopened powder below 25°C, protected from light. Once reconstituted, the solution should be used immediately or within the validated stability period. Do not use after the expiry date printed on the packaging.

Proper storage of Ceftriaxon MIP is essential to maintain its efficacy and safety. The following guidelines should be followed:

• Unopened vials: Store below 25°C. Keep the vials in the outer carton to protect from light. Do not freeze the powder.
• Reconstituted solution: Chemical and physical in-use stability has been demonstrated for up to 6 hours at 25°C (or up to 24 hours at 2-8°C) for certain diluents, but from a microbiological standpoint, the product should be used immediately after reconstitution. If not used immediately, storage times and conditions prior to use are the responsibility of the user.
• Appearance: The reconstituted solution should be a pale yellow to amber-coloured clear liquid. Do not use if the solution is cloudy, contains particles, or has changed colour significantly.
• Expiry date: Do not use Ceftriaxon MIP after the expiry date (EXP) stated on the carton and vial label.
• Disposal: Do not dispose of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help to protect the environment.

Healthcare facilities should follow their institutional policies for the storage, preparation, and handling of reconstituted injectable antibiotics. Aseptic technique must be used throughout the reconstitution process. Any unused solution should be discarded in accordance with local guidelines for pharmaceutical waste disposal.

What Does Ceftriaxon MIP Contain?

Quick answer: Each vial contains 2 g of ceftriaxone (as ceftriaxone disodium salt, equivalent to approximately 2.39 g of ceftriaxone disodium 3.5-hydrate). No other excipients are present in the powder formulation.

Ceftriaxon MIP is a remarkably simple formulation containing only the active pharmaceutical ingredient:

• Active ingredient: Ceftriaxone 2 g (as ceftriaxone disodium 3.5-hydrate)
• Excipients: None. The powder contains no additional excipients, preservatives, or stabilisers.
• Sodium content: Each 2 g vial contains approximately 166 mg (7.2 mmol) of sodium. This should be taken into consideration for patients on a controlled sodium diet.

The molecular formula of ceftriaxone disodium is C₁₈H₁₆N₈Na₂O₇S₃ with a molecular weight of approximately 661.6 g/mol. Ceftriaxone is a white to yellowish-orange crystalline powder that is freely soluble in water and sparingly soluble in methanol. The reconstituted solution has a pH of approximately 6.0-8.0 depending on the concentration and diluent used.

The powder is supplied in clear glass vials with rubber stoppers and aluminium seals. The product is available as a single-vial pack. Each vial is intended for single use only — any unused solution remaining after dose preparation should be discarded.

Compatible diluents for reconstitution include 0.9% sodium chloride solution, 5% glucose solution, and 10% glucose solution. The solution must not be reconstituted with calcium-containing diluents such as Ringer's solution or Hartmann's solution. The reconstituted solution may also be further diluted in compatible infusion bags for administration as a prolonged infusion.

Frequently Asked Questions